Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion’s US subsidiary, Celltrion USA, Inc., has decided on a rights offering worth USD 532.1M (approx. KRW 782.4B) to fund the acquisition of a US API manufacturing facility and secure working capital.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decision on Capital Increase by Rights Offering (Major Management Matters of Subsidiary)
- Subsidiary Name: Celltrion USA, Inc. (CEO: Bon-Joong Kim, Main Business: Pharmaceutical Wholesale & Retail)
- Class and Number of New Shares: 100 common shares (Total issued shares before offering: 3,050 common shares)
- Par Value per Share: KRW 0.15 (USD 0.0001)
- Purpose of Fund Raising:
- Acquisition of Securities of Other Corporations: KRW 772,107,040,000 (USD 525,100,000 / To acquire a US API facility entity)
- Working Capital: KRW 10,292,800,000 (USD 7,000,000)
- Total Fund Raising: KRW 782,399,840,000 (approx. KRW 782.4B / USD 532,100,000)
- Applied Exchange Rate: Initial basic exchange rate on December 11, 2025 (USD/KRW 1,470.40)
- Method of Capital Increase: Rights offering to existing shareholders (0.0327869 new shares per 1 existing share)
- Payment Schedule (Tranche Execution):
- 1st Payment: USD 445,800,000 / Payment Date: December 18, 2025
- 2nd Payment: USD 86,300,000 / Scheduled Period: During 2026
- Board Resolution Date: December 11, 2025
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of 1st Payment Execution on December 18, 2025 and 2026 Progress
This disclosure details the decision by Celltrion’s US subsidiary, Celltrion USA, to raise approx. KRW 782.4B via a rights offering to acquire a US API manufacturing facility, making it important to monitor the execution of the 1st payment on December 18, 2025 and the 2nd payment during 2026. Tracking the capital injection schedule ensures verification of capital execution and acquisition progress. Execution updates and capital payment status can be verified through upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports) or subsequent regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
